The main issue in terms of the ethics of BPC-157 and TB-500 is that both substances are still considered experimental drugs, and that their potential risks and benefits have yet to be fully elucidated
Key regulatory points for Epitalon Australia compliance: Epitalon is not approved by the Therapeutic Goods Administration (TGA) as a registered medicine for human or veterinary use It is classified strictly for laboratory and research purposes, not for human consumption Supply, import, and handling of research peptides fall under Australian regulatory oversight, and institutions should confirm current scheduling status directly through TGA resources before procurement Any research involving human subjects must comply with Research Ethics Committee approval and applicable Good Clinical Practice standards Marketing or supplying Epitalon with therapeutic claims, or implying suitability for human treatment, falls outside permitted research-use classifications Researchers and institutions should treat Epitalon strictly as a laboratory reagent, ensuring internal documentation, handling protocols, and communications consistently reflect its research-only status
Manufactured in a GMP-certified facility with strict quality standards to ensure purity, consistency, and reliable nutritional support in every batch
Furthermore, removal of the methylene carboxy group at the C-terminal of 23 resulted in a less efficient IRAP inhibitor
